Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has secured a deal with Cellares, a U.S.-based cell therapy production platform, to bolster its manufacturing capacity for CAR-T therapies. In return for granting exclusive access to several of its fully automated systems, Cellares is set to receive up to USD 380 million in upfront and milestone payments.
This strategic partnership follows two previous agreements between BMS and Cellares for the production of two undisclosed CAR-T cell therapies.- Flcube.com
